On October 1, 2021 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, reported that two abstracts featuring targeted radiotherapies in combination with CD47 antibody immunotherapy for solid tumor and hematologic indications have been accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy for Cancer (SITC 2021) (Press release, Actinium Pharmaceuticals, OCT 1, 2021, View Source [SID1234590656]). Actinium’s abstract titles and presentation logistics are as follows:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title: Enhancement of the anti-tumor effects of CD47 blockade in solid tumors by combination with targeted radioimmunotherapy
Poster Number: 589
Location: Poster Hall
Dates and Times: 11/12/2021 – 11/14/2021, 7:00 am – 5:00 pm
Title: Anti-CD33 actinium-225 targeted radioimmunotherapy enhances the biologic activity of anti-CD47 antibody immunotherapy in preclinical models of acute myeloid leukemia
Poster Number: 590
Location: Poster Hall
Dates and Times: 11/12/2021 – 11/14/2021, 7:00 am – 5:00 pm
Sandesh Seth, Actinium’s Chairman and CEO, said, "We are excited to highlight our latest R&D efforts focused on combinations of actinium-225 based targeted radiotherapies with CD47 immunotherapies, which has emerged as one of the most active targets in immunotherapy drug development of late, in solid tumors and blood cancers. We are thrilled that our abstracts, which are a product of our enhanced R&D capabilities, have been accepted at SITC (Free SITC Whitepaper). This body of work stemmed from our AWE technology platform, R&D capabilities in immuno-oncology and new laboratory facilities. We’ve highlighted our intention to move into solid tumor indications and immunotherapy combinations outside of the solid tumor work we are doing with our partner Astellas, so it is incredibly exciting to unveil our first initiatives in these areas at SITC (Free SITC Whitepaper). We look forward to presenting data from our work at the conference and continuing to be at the front lines of targeted radiotherapy development leveraging our deep technical knowledge, supply chain and clinical capabilities."
SITC is being held November 10 – 14, 2021 at the Walter E. Washington Convention Center in Washington, D.C. The full posters will be made available on the presentations page of Actinium’s website after the embargo is lifted at 8 AM ET on November 9, 2021.